Technology Bundle ID
TAB-2400

Cytochromes P450 CYP2J and CYP2C Polyclonal Antibodies and Recombinant Proteins

Applications
Research Materials
Linked ID
E-153-2011-0
Lead Inventors
Darryl Zeldin (NIEHS)
Development Status
In vitro data available
ICs
NIEHS
The National Institutes of Health announces polyclonal antibodies against mouse cytochrome P450s CYP2J and CYP2C. Cytochrome P450s catalyze the metabolism of a wide range of exogenous compounds, including drugs, industrial chemicals, environmental pollutants, and carcinogens. The 2C family of cytochrome P450 metabolizes an extensive number of drugs which include tolbutamide, S-Warfarin, mephenytoin, diazepam and taxol. Many of the P450 enzymes are also active in the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species. The 2J family is expressed at high levels in the heart and has been shown to metabolize both arachidonic acid and linoleic acid. The CYP2J and CYP2C subfamily members have a wide tissue distribution and may be useful as model systems for studies of cardiovascular disease, drug metabolism and toxicity.

Recombinant proteins of mouse cytochrome P450s CYP2C and CYP2J have also been expressed and can be used as controls in immunoblotting, as well as for metabolism studies.
Commercial Applications
  • These antibodies can be used to study the expression of the P450s in various tissues by immunohistochemistry and immunoblotting.
  • The recombinant proteins can be used as controls in immunoblotting as well as for metabolism studies.
Competitive Advantages
  • The CYP2J and CYP2C subfamily members have a wide tissue distribution and may be useful as model systems for studies of cardiovascular disease, drug metabolism and toxicity.

Request More Info

Licensing Contact: